Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.

Sepsis was reported in three comparison groups; No significant difference was observed in the BTKi + anti-CD20 vs another comparator: RR 0.48 (95% CI: 0.12–1.84, I 2 = 69%, 4 trials), or in the BTKi monotherapy vs another comparator: RR 0.50 (95% CI: 0.25–1.01, I 2 = 0%, 5 trials), although the latter showed a trend toward reduced risk (Fig. 5 A–B).

also in 53,322 other papers